Related Experiment Video
Updated: Jul 31, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Apolipoprotein E gene and sporadic frontal lobe dementia
M Stevens1, C M van Duijn, P de Knijff
1Department of Neurology, University Hospital Rotterdam, The Netherlands.
Neurology
|June 1, 1997
Summary
Individuals with the apolipoprotein E (APOE) gene variant apoE4E4 face a significantly higher risk of developing frontal lobe dementia (FLD). Increased APOE*4 alleles correlate with an earlier age of disease onset.
Area of Science:
- Neuroscience
- Genetics
- Epidemiology
Background:
- The apolipoprotein E (APOE) gene is implicated in various neurodegenerative conditions.
- Frontal lobe dementia (FLD) is a debilitating condition affecting cognitive functions.
- Understanding genetic risk factors is crucial for early diagnosis and intervention.
Purpose of the Study:
- To investigate the association between APOE gene variants and the risk of developing FLD.
- To determine the impact of APOE genotype on the age of onset for FLD.
- To analyze FLD risk within a population-based cohort.
Main Methods:
- Retrospective analysis of 34 patients with clinically diagnosed FLD.
- Genotyping for apolipoprotein E (APOE) alleles.
- Statistical analysis including odds ratios and confidence intervals, adjusted for covariates.
Main Results:
- A significant increased risk of FLD was observed for the apoE4E4 genotype (odds ratio, 4.9; 95% CI, 1.1-20.1).
- A dose-dependent relationship was found: the more APOE*4 alleles, the earlier the age of disease onset.
- The apoE4E4 genotype was identified as a risk factor in this Dutch population-based study.
Conclusions:
- Homozygosity for the APOE*4 allele is associated with an elevated risk of developing FLD.
- APOE genotype influences the age at which FLD manifests.
- Further research into APOE's role in FLD pathogenesis is warranted.
More Related Videos
09:38Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...